Diagnocure Grants Stock Options To Senior Advisor
17 September 2013 - 9:30PM
OTC Markets
Diagnocure Grants Stock Options To Senior Advisor
#ReleaseContent TABLE
{
BORDER-COLLAPSE: collapse
}
TR.cnwUnderlinedCell TD
{
BORDER-BOTTOM: #000000 1px solid
}
TR.cnwDoubleUnderlinedCell TD
{
BORDER-BOTTOM: #000000 3px double
}
TR.cnwBoldUnderlinedCell TD
{
BORDER-BOTTOM: #000000 3px solid
}
TD.cnwUnderlinedCell
{
BORDER-BOTTOM: #000000 1px solid
}
TD.cnwDoubleUnderlinedCell
{
BORDER-BOTTOM: #000000 3px double
}
TD.cnwBoldUnderlinedCell
{
BORDER-BOTTOM: #000000 3px solid
}
#ReleaseContent TABLE.cnwBorderedTable TD
{
BORDER-RIGHT: black 1px solid;
PADDING-RIGHT: 2px;
BORDER-TOP: black 1px solid;
PADDING-LEFT: 2px;
PADDING-BOTTOM: 2px;
BORDER-LEFT: black 1px solid;
PADDING-TOP: 2px;
BORDER-BOTTOM: black 1px solid;
BORDER-COLLAPSE: collapse
}
#ReleaseContent TABLE TD
{
PADDING-RIGHT: 2px;
PADDING-LEFT: 2px;
PADDING-BOTTOM: 2px;
PADDING-TOP: 2px
}
Diagnocure Grants Stock Options To Senior Advisor
PR Newswire
QUEBEC CITY, Sept. 17, 2013
Vesting Linked To Improvement of Shareholder Value
QUEBEC CITY, Sept. 17, 2013
/PRNewswire/ - DiagnoCure Inc. (TSX:
CUR)(TCQX: DGCRF) (the "Corporation") reports the granting, as
of
today, of 500,000 options to Richard
Bordeleau who was appointed Senior
Advisor to the Board on September
1st, 2013. The vesting of these options is tied
to the delivery of
measurable milestones of which twenty percent can be vested during
Mr.
Bordeleau's mandate as Senior Advisor. The options granted will
vest in
several installments which are all linked to strong
value-creating
milestones. The other options reported on SEDI are tied to
several
stringent vesting conditions, which include the possibility
that
Mr. Bordeleau be entrusted with other significant
responsibilities. If
any of the milestones do not materialize, then the options related
to
this condition will not vest.
"We are granting these options to Mr. Bordeleau because we
strongly
believe that his contribution to DiagnoCure will create value for
our
shareholders. The vesting will occur as Mr. Bordeleau fulfills
his
critical mandates, notably by implementing short-term initiatives
and
developing mid- to long-term opportunities" stated Dr.
Yves Fradet,
Chairman of the Board and President and Chief Medical
Officer.
About DiagnoCure
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation
that
develops and commercializes high-value cancer diagnostic tests
that
increase clinician and patient confidence in making critical
treatment
decisions. In 2008, the Corporation launched a colorectal
cancer
staging test through its U.S. CLIA laboratory.
PrevistageTM GCC is currently available for licensing.
The Corporation has granted a
worldwide exclusive license on the diagnostic applications of
its
proprietary molecular biomarker PCA3 to Gen-Probe, now a
wholly-owned
subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3
prostate
cancer test is commercialized in Europe under CE mark and is approved
for commercialization in Canada
and the United States. For
more
information, please visit www.diagnocure.com.
Forward?looking statements
This release may contain forward?looking statements that involve
known
and unknown risks, uncertainties and assumptions that may cause
actual
results to differ materially from those expected.
Forward-looking
statements can be identified by the use of the conditional or
forward-looking terminology such as "anticipates", "assumes",
"believes", "estimates", "expects", "intend", "may", "plans",
"projects", "should", "will", or the negative thereof or other
variations thereon. Forward-looking statements also include any
other
statements that do not refer to historical facts. All such
forward-looking statements are made pursuant to the
"safe-harbour"
provisions of applicable Canadian securities laws. By their
very
nature, forward?looking statements are based on expectations
and
hypotheses and also involve risks and uncertainties, known and
unknown,
many of which are beyond DiagnoCure's control. Forward-looking
statements are presented for the purpose of assisting investors
and
others in understanding certain key elements of the
Corporation's
current objectives, strategic priorities, expectations and plans,
and
in obtaining a better understanding of the Corporation's business
and
anticipated operating environment. Readers are cautioned that
such
information may not be appropriate for other purposes and that
they
should not place undue reliance on these forward?looking
statements.
For instance, any forward-looking statements regarding the outcome
of
research and development projects, clinical studies and future
revenues, including those related to PROGENSA® PCA3, are based
on
management expectations and such outcome may vary materially
depending
on global political and economic conditions, dependence on
collaboration partners, uncertainty of healthcare reimbursement,
and
marketing and distribution challenges. In addition, the reader
is
referred to the applicable general risks and uncertainties
described in
DiagnoCure's most recent Annual Information Form under the
heading
"Risk Factors". DiagnoCure undertakes no obligation to publicly
update
or revise any forward?looking statements contained herein
unless
required by the applicable securities laws and regulations.
SOURCE DiagnoCure inc.
Diagnocure (CE) (USOTC:DGCRF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnocure (CE) (USOTC:DGCRF)
Historical Stock Chart
From Jul 2023 to Jul 2024